Kidney Cancer: A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal
Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010)
What are the good or bad effects of atezolizumab versus placebo on you and your Renal
Cell Carcinoma (RCC)?
Basic Study Information
Purpose:Location: Cancer Center
You will be randomly assigned to one of the following treatment groups: atezolizumab
or placebo. Neither you nor your study doctor may choose the group you will be in.
You will have a 50/50 chance of being placed in either group.
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT03024996?term=wo39210&rank=1
Study Reference #: IGUK17001
Lead Researcher (Principal Investigator)
Lead Researcher: Elizabeth Guancial
Study Contact InformationStudy Coordinator: Ayesha Khan
Phone: (585) 275-3351
Additional Study Details
Learn More About These Conditions
More information about Carcinoma, Renal Cell
More information about Kidney Cancer
Trial Not Found
The study you are looking for is not active at this time.
Return to Search